jRCT2031220222进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of subcutaneous anakinra in Japanese patients with Still's disease (SJIA and AOSD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 15
- 主要终点
- ACR30 response
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 0age 8month old over 至 No limit（—）
- 性别
- All
入选标准
- •Male and female patients, 8 months of age or older with a body weight >_10 kg
- •Diagnosis of Still's disease.
- •If < 16 years of age at disease onset, the diagnosis is made according to adapted ILAR criteria i.e., CARRA criteria for SJIA. If >_ 16 years of age at disease onset, the diagnosis is made according to Yamaguchi criteria for AOSD.
- •Active disease confirmed by the following three signs and symptoms. a. Active arthritis in >_ 1 joint. b. CRP > 30 mg/L. c. At least one fever episode (>_ 38.0 degree Celsius) attributable to the disease within one week before enrollment.
- •The result of tuberculosis test within 8 weeks prior to enrollment is negative.
排除标准
- •Previous or current treatment with anakinra, or any other Interleukin-1 (IL-1) inhibitor except for canakinumab. Previous treatment with canakinumab is allowed if canakinumab was discontinued for reasons other than lack of efficacy and after a washout period of minimum 130 days (Refer to Exclusion Criteria 5h). Patients who have discontinued canakinumab because of insufficient effect or refractory disease are not allowed to be enrolled in the study.
- •Use of the following therapies prior to enrollment. a. Narcotic analgesics within 24 hours prior to enrollment. b. Diaminodiphenyl sulfone within 1 week prior to enrollment or etanercept within 2 weeks prior to enrollment. c. Intraarticular, intramuscular, or intravenous administration of glucocorticoids within 72h (3 days) prior to enrollment, or intravenous immunoglobulin within 4 weeks prior to enrollment. d. Intravenous immunoglobulin with proven Still's disease modifying effect, leflunomide, infliximab, or adalimumab within 8 weeks prior to enrollment. e. Thalidomide within 72h (3 days) prior to enrollment, cyclosporine within 5 weeks prior to enrollment, mycophenolate mofetil within 1 week prior to enrollment, 6-mercaptopurine within 48h (2 days) prior to enrollment, azathioprine within 72h (3 days) week prior to enrollment, cyclophosphamide within 96h (4 days) prior to enrollment, chlorambucil (not approved in Japan) within 48h (2 days) prior to enrollment, or any other immunosuppressant within 12 weeks prior to enrollment. f. Tocilizumab within 4 weeks prior to enrollment or any other immunomodulatory medication within 4 half-lives prior to enrollment. g. Rituximab within 13 weeks prior to enrollment. h. Canakinumab within 130 days prior to enrollment.
- •Live vaccines within 4 weeks prior to enrollment.
- •Known presence or suspicion of active, chronic, or recurrent bacterial, fungal, or viral infections, including but not limited to tuberculosis, HIV infection, Covid-19 infection, or hepatitis B or C infection at baseline. Patients with acute or chronic HBV (i.e., with positive HBsAg, except if a documented history of vaccination), or at risk of HBV reactivation (i.e., with negative HBsAg AND positive anti-HBc) will be excluded.
- •Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests. a. AST or ALT > 5 x upper limit of normal (ULN), or b. AST or ALT > 3 x ULN accompanied by elevated bilirubin > 2 x ULN.
- •Presence of severe chronic kidney disease (CKD) grades 4 and 5 (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73m2).
- •Presence of neutropenia (absolute neutrophil count [ANC] < 1.5 x 10^9/L).
- •Presence of thrombocytopenia (platelets count < 100 x 10^9/L).
- •Presence or suspicion of MAS at baseline.
- •History or diagnosis of MAS within the last 4 weeks prior to enrollment.
结局指标
主要结局
ACR30 response
时间窗: Week 2
ACR30 response at Week 2 with absence of fever attributable to the disease during the 7 days preceding Week 2 visit.
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C MutatioAdvanced or metastatic solid tumors with a KRAS-G12C mutation, Advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS-G12C mutation and who are KRAS-G12Ci naïveMedDRA version: 21.1Level: PTClassification code: 10028980Term: Neoplasm Class: 100000004864CTIS2022-501363-40-00avire Pharma Inc.110
进行中（未招募）
1 期
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code: 10018937Term: Haemophilia A Class: 10010331CTIS2023-505801-17-00Swedish Orphan Biovitrum AB (publ)24
招募中
1 期
A multi-site, open-label, sequential-group, multiple-ascending-dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of Lu AG13909 in patients with congenital adrenal hyperplasiaCongenital adrenal hyperplasiaMedDRA version: 20.0Level: LLTClassification code: 10010323Term: Congenital adrenal hyperplasia Class: 10010331CTIS2023-503711-15-00H. Lundbeck A/S36
进行中（未招募）
1 期
A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinomaMedDRA version: 20.1Level: LLTClassification code: 10063001Term: Human papilloma virus infection Class: 10021881Treatment of human papilloma virus (HPV) associated infections and cancersCTIS2024-514413-36-00Bluesky Immunotherapies GmbH12
进行中（未招募）
1 期
MK-1403 Single Dose Formulation PK StudyMedDRA version: 20.0Level: LLTClassification code: 10003601Term: Atherosclerosis Class: 10047065AtherosclerosisCTIS2023-507984-20-00Merck Sharp & Dohme LLC16